GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Savara Inc.
Shares of Savara, a biopharmaceutical company focused on treating rare lung diseases, reflect the sector's binary risks. The price trajectory depends entirely on the results of clinical trials and regulatory decisions regarding its lead drug.
Share prices of companies in the market segment - Pharma immune
Savara Inc. is a biopharmaceutical company focused on rare respiratory diseases such as autoimmune pulmonary alveolar proteinosis. We've placed it in the Pharmaceuticals (Immunology) segment, where breakthrough treatments are developed. The chart below illustrates the dynamics of this cutting-edge medical field.
Broad Market Index - GURU.Markets
Savara Inc. is a pharmaceutical company developing inhaled drugs for the treatment of rare lung diseases. It is a component of the GURU.Markets index, and the chart below shows how its stock compares to the market, reflecting investor expectations.
Change in the price of a company, segment, and market as a whole per day
SVRA - Daily change in the company's share price Savara Inc.
For Savara, a biopharmaceutical company, change_co is a measure of reaction to clinical and regulatory news. Daily fluctuations reflect the volatility associated with the development of drugs for rare lung diseases. This metric is a key element in biotech company analysis on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Pharma immune
Savara Inc. is a biotech company. This chart highlights the sector's extreme volatility. Comparison with SVRA, which focuses on treating rare lung diseases, helps to assess it as a high-risk, clinical-data-driven asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Savara is a biopharmaceutical company specializing in drugs for rare lung diseases. Biotechnology is a volatile sector. The chart below shows average daily fluctuations in this sector, providing context for analyzing Savara's stock performance.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Savara Inc.
Savara is a biopharmaceutical company focused on immunology. Its shares, like many in the sector, are highly volatile and react to news about clinical trials. These science-driven movements are part of the complex and diverse landscape of the entire stock market.
Annual dynamics of market capitalization of the market segment - Pharma immune
Savara Inc. is a late-stage biopharmaceutical company focused on treating rare lung diseases. Its stock price is entirely dependent on clinical trial results and regulatory decisions. The chart reflects the high risks and potential for breakthroughs in this area.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Savara is a clinical-stage biotech whose fate depends on scientific breakthroughs, not the state of the economy. Its stock price reflects investor hopes for the success of new drug trials. The company's chart exists in a world of its own, where the main events are data releases.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Savara Inc.
Oruka, a preclinical biotech company. The sharp monthly fluctuations on the chart reflect news about its research platform and partnerships with major pharmaceutical companies that are validating its technology and providing funding.
Monthly dynamics of market capitalization of the market segment - Pharma immune
Savara Inc. is a pharmaceutical company focused on rare lung diseases. Its future depends entirely on the success of clinical trials and regulatory approval. The dynamics of the biotech sector demonstrate the risk appetite of investors in science-intensive developments. Against this backdrop, Savara's story is a bet on one specific molecule.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Savara Inc. is an orphan pharmaceutical company developing therapies for rare respiratory diseases. The company's future depends on the success of its clinical trials and regulatory decisions. The broader market chart serves as just a backdrop to demonstrate how news about its lead drug for a rare lung disease has driven its stock price completely independently.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Savara Inc.
Savara is a biotech company developing drugs to treat rare lung diseases. Its weekly stock price is highly volatile and dependent on clinical trial news, as is typical for this sector.
Weekly dynamics of market capitalization of the market segment - Pharma immune
Savara is a biotech company focused on rare diseases. Comparing its weekly performance to the broader biotech sector only highlights its uniqueness. The chart below shows how news about its clinical trials drives its stock price movement independently of overall trends.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Savara, a biotech company, lives in a world of its own. Its performance is driven by clinical trial data. A chart comparing the stock to the S&P 500 clearly demonstrates how its stock can rise or fall, completely ignoring the broader market.
Market capitalization of the company, segment and market as a whole
SVRA - Market capitalization of the company Savara Inc.
Savara's market capitalization chart is a focused bet on treating a rare lung disease. This biotech company's performance is entirely dependent on the success of its lead experimental drug. It's a classic biotech story, where the entire path from development to potential approval is reflected in wild stock price fluctuations.
SVRA - Share of the company's market capitalization Savara Inc. within the market segment - Pharma immune
Savara is a pharmaceutical company developing treatments for rare lung diseases. Its market share reflects investor expectations for its lead drug, which treats autoimmune pulmonary alveolar proteinosis. The chart below shows the market's weighting for its chances of success in this orphan drug niche.
Market capitalization of the market segment - Pharma immune
Savara is a biopharmaceutical company developing inhaled drugs for the treatment of rare lung diseases. The graph below shows the immunopharmaceutical sector. It illustrates the potential for companies targeting orphan diseases, where competition is lower and drug prices are higher.
Market capitalization of all companies included in a broad market index - GURU.Markets
This chart shows the fight against a rare lung disease. Savara is developing an inhaled drug for the treatment of autoimmune pulmonary alveolar proteinosis. Its volatile line on the chart reflects the hopes of patients and investors for the success of this single product.
Book value capitalization of the company, segment and market as a whole
SVRA - Book value capitalization of the company Savara Inc.
Savara's book value is derived from its financial reserves and intellectual property in drugs for rare lung diseases. This represents focused scientific capital for solving complex medical problems. The chart shows how the biotech company manages its research budget, advancing its lead candidate through key clinical trial phases.
SVRA - Share of the company's book capitalization Savara Inc. within the market segment - Pharma immune
Savara is a biotech company developing drugs to treat rare lung diseases. Its assets are intellectual property. The chart shows a minimal share of physical assets, as it is an R&D company in the clinical stage.
Market segment balance sheet capitalization - Pharma immune
Developing drugs for rare lung diseases, like Savara's, is a knowledge-intensive but relatively "easy" business at the R&D stage. Its value lies in its patents. Compared to the capital-intensive pharmaceutical sector, the company's model doesn't require the ownership of large manufacturing plants.
Book value of all companies included in the broad market index - GURU.Markets
Savara's assets are not factories, but capital focused on developing drugs for rare lung diseases. Its book value reflects the company's financial resources for late-stage clinical trials, the final step before market entry. The chart illustrates its scale in this niche.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Savara Inc.
For Savara, which develops drugs for rare lung diseases, market capitalization is a bet on the success of its lead candidate. The ratio to book value (its cash value) reflects how much investors believe the company can bring its drug to market.
Market to book capitalization ratio in a market segment - Pharma immune
Savara is a biopharmaceutical company developing therapies for rare lung diseases. Its high valuation on this chart reflects the success of its lead drug in clinical trials, which could completely change the company's fortunes.
Market to book capitalization ratio for the market as a whole
Savara is a late-stage biopharmaceutical company focused on treating rare lung diseases. Its valuation depends on the success of its lead drug in clinical trials. This metric for such companies reflects the binary nature of biotech investing, where the success of a single drug can lead to multiple price increases.
Debts of the company, segment and market as a whole
SVRA - Company debts Savara Inc.
Savara, a biopharmaceutical company focused on rare lung diseases, is in late-stage clinical trials. The company is raising capital, including debt, to prepare for the potential commercial launch of its lead product. This chart shows the cost of bringing the drug to the finish line.
Market segment debts - Pharma immune
Savara is a biopharmaceutical company focused on developing treatments for rare respiratory diseases. Its lead candidate is in late-stage development. This timeline shows how the company is funding its expensive clinical trials and preparing for potential commercialization, a critical and capital-intensive stage for any biotech company.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Savara Inc.
Savara is a pharmaceutical company specializing in developing drugs for rare respiratory diseases. The path from drug development to commercialization is long, expensive, and fraught with high risks. This chart illustrates the company's reliance on debt to finance its lengthy and costly clinical trials.
Market segment debt to market segment book capitalization - Pharma immune
Savara is a biopharmaceutical company focused on developing drugs to treat rare lung diseases. Clinical trials in this area are complex and expensive. This chart shows how the company finances its research and development, comparing its debt structure to the overall financial landscape of the biotech sector.
Debt to book value of all companies in the market
Savara Inc. is a pharmaceutical company developing drugs to treat rare lung diseases. Clinical trials in this area are expensive and time-consuming. How dependent is Savara on debt financing to advance its research? This chart of total market debt allows us to assess its financial vulnerability and survival strategy.
P/E of the company, segment and market as a whole
P/E - Savara Inc.
Savara is a biopharmaceutical company developing therapeutics for rare lung diseases. This chart reflects investor expectations for its lead candidate. The company's valuation is highly dependent on clinical trial results and potential regulatory approval, which could dramatically change its prospects.
P/E of the market segment - Pharma immune
Savara is an orphan lung company focused on developing treatments for rare respiratory diseases. This chart shows the average valuation for the sector, providing investors with context for assessing the scientific potential and risks associated with Savara's portfolio.
P/E of the market as a whole
Savara is a biopharmaceutical company focused on developing drugs to treat rare lung diseases. The valuation of such companies often takes on a life of its own, depending on the success of clinical trials. Does comparing this chart reveal the extent to which Savara investors are ignoring the broader market picture, betting solely on its science?
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Savara Inc.
Savara is a pharmaceutical company developing inhaled medications for rare lung diseases. This chart reflects market expectations for the success of its key product. Future revenue is entirely dependent on the results of late-stage clinical trials and subsequent regulatory approval.
%20P%2FE%20Savara%20Inc.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Savara-Inc.&v=1772612591679 "Chart of the company's future (projected) P/E Savara Inc.")
Future (projected) P/E of the market segment - Pharma immune
Savara is a pharmaceutical company developing inhaled medications for the treatment of rare lung diseases such as autoimmune pulmonary alveolar proteinosis. This chart shows industry forecasts. This helps compare how the market views the potential of Savara's key drug to become the first approved treatment for this serious condition.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-immune&v=1772612591708 "Future (projected) P/E graph of the market segment - Pharma immune")
Future (projected) P/E of the market as a whole
Savara Inc. is a biopharmaceutical company developing therapies for rare lung diseases. Its valuation depends almost entirely on the success of its lead drug in clinical trials. This market sentiment chart determines how much risk investors are willing to take when investing in biotech companies at a critical stage of development.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772612591740 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Savara Inc.
Savara Inc. is an orphan pharmaceutical company developing therapies for rare lung diseases. Being in late-stage clinical trials, it incurs significant expenses. This chart illustrates the final and most expensive stage of drug development before potential approval and market launch.
Profit of companies in the market segment - Pharma immune
Savara is a pharmaceutical company developing inhaled therapies for rare lung diseases. This chart, which shows the pharmaceutical sector's profitability, highlights the investment climate. Their lead drug targets a rare disease, giving them the potential to receive orphan drug designation and accelerated approval if clinical trials are successful.
Overall market profit
Savara Inc. is a pharmaceutical company specializing in the treatment of rare lung diseases. Its lead candidate is an inhaled drug for treating lung infections. The company's success depends on regulatory approval. This chart of overall market returns shows the investment climate, which is important for funding expensive late-stage clinical trials.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Savara Inc.
Savara is a biopharmaceutical company developing inhaled therapies for rare lung diseases. Its lead candidate targets autoimmune pulmonary alveolar proteinosis. This timeline reflects analyst expectations for clinical trial success and potential approval of this potentially first-in-class drug.
%20profit%20of%20the%20company%20Savara%20Inc.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Savara-Inc.&v=1772612591780 "Graph of future (projected) profit of the company Savara Inc.")
Future (predicted) profit of companies in the market segment - Pharma immune
Savara is a pharmaceutical company developing inhaled drugs for the treatment of rare lung diseases. Its main asset is in late-stage development. The company's future depends on regulatory approval. This biotech chart reflects the general expectations for companies operating in the orphan (rare) disease niche, where the commercial potential is very high.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-immune&v=1772612591802 "Graph of future (predicted) profits of companies in a market segment - Pharma immune")
Future (predicted) profit of the market as a whole
Savara Inc. is a pharmaceutical company specializing in the treatment of rare lung diseases. Its future is determined by the success of clinical trials. The overall economic outlook, reflected in this chart, impacts the investment climate and the availability of capital to continue costly research and development.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772612591806 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Savara Inc.
Savara is a pharmaceutical company developing inhaled drugs for rare lung diseases. For a late-stage clinical company, this chart is key. It shows how investors assess the potential future sales of its lead candidate, betting on its approval and commercial success in a niche but important field.
P/S market segment - Pharma immune
Savara Inc. is a biopharmaceutical company developing treatments for rare lung diseases. Being in late-stage clinical development, its valuation is closely tied to the likelihood of approval of its lead product. This chart reflects the average valuation in the sector, providing context for understanding how the market views Savara's chances of commercial success.
P/S of the market as a whole
Savara is a pharmaceutical company developing inhaled therapies for rare lung diseases such as autoimmune pulmonary alveolar proteinosis. This chart, which reflects market revenue estimates, is a measure of Savara's hope. It shows how much investors value the company's potential to offer lifesaving treatments for patients with orphan diseases.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Savara Inc.
Savara is a pharmaceutical company developing therapies for rare lung diseases. Its lead candidate is designed to treat autoimmune pulmonary alveolar proteinosis. This chart reflects investor expectations for the future success of this drug, which, if approved, could become the first and only treatment for this disease.
%20P%2FS%20Savara%20Inc.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Savara-Inc.&v=1772612591870 "The graph of the company's future (projected) P/S Savara Inc.")
Future (projected) P/S of the market segment - Pharma immune
Savara Inc. is an orphan pharmaceutical company specializing in the development of innovative treatments for rare respiratory diseases, such as pulmonary alveolar proteinosis. This chart reflects average future revenue expectations in the pharmaceutical sector. It provides an insight into how the market perceives the potential of Savara's drugs to address unmet medical needs.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20immune&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-immune&v=1772612591895 "Future (projected) P/S market segment graph - Pharma immune")
Future (projected) P/S of the market as a whole
Savara Inc. is a pharmaceutical company specializing in developing inhaled drugs for the treatment of rare lung diseases. This chart shows the market's collective expectations for future revenue. Savara's success in clinical trials could offer patients new, more effective treatments, which is part of the overall optimism among investors in the biotech sector.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772612591898 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Savara Inc.
This chart shows the revenue of Savara, a pharmaceutical company developing inhaled drugs for rare lung diseases. During clinical development, its revenue may be minimal or nonexistent. Changes in revenue will reflect progress in research and the potential future commercial success of its products.
Sales of companies in the market segment - Pharma immune
Savara Inc. is an orphan pharmaceutical company developing inhaled therapies for rare lung diseases. This chart shows the potential market for its products. The company's flagship drug targets a rare disease for which there are no approved treatments, and if successful, Savara could fill this entire niche, changing patients' lives.
Overall market sales
Savara Inc. is a pharmaceutical company specializing in the treatment of rare lung diseases. Its future depends on successful clinical trials and regulatory approval. The overall economic situation, shown in this chart, affects the availability of capital to fund such highly specialized research.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Savara Inc.
Savara is a pharmaceutical company developing therapies for rare lung diseases. Future revenue depends on the success of its lead candidate in clinical trials and its subsequent approval. The chart reflects analyst expectations for the drug's commercial potential.
%20sales%20of%20the%20company%20Savara%20Inc.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Savara-Inc.&v=1772612591970 "Schedule of future (projected) sales of the company Savara Inc.")
Future (projected) sales of companies in the market segment - Pharma immune
Savara is a biopharmaceutical company specializing in the development of inhaled therapies for the treatment of rare lung diseases. Its lead candidate is designed for the treatment of autoimmune pulmonary alveolar proteinosis. This chart shows the forecast for the overall pharmaceutical market, where Savara is aiming to fill a niche in the field of orphan respiratory diseases.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-immune&v=1772612591978 "Schedule of future (projected) sales of companies in the market segment - Pharma immune")
Future (projected) sales of the market as a whole
Savara Inc. is a pharmaceutical company specializing in the treatment of rare lung diseases. Its lead candidate is an inhaled drug for the treatment of chronic infections. The company's success depends on the results of clinical trials and FDA approval. This chart shows general market sentiment, but for Savara, scientific evidence of the effectiveness of its therapy is key.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772612592020 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Savara Inc.
Savara is a pharmaceutical company developing inhaled drugs for rare lung diseases. In late-stage clinical trials, it is incurring significant expenses as it prepares for a potential product launch. This chart shows its net losses—the final push before potential commercialization and market entry.
Market segment marginality - Pharma immune
Savara is a pharmaceutical company specializing in developing treatments for rare respiratory diseases such as pulmonary alveolar proteinosis. Profitability depends on the success of their lead drug candidate in clinical trials and subsequent approval. This graph reflects research costs. Investors evaluate it in the context of potential benefits to patients.
Market marginality as a whole
Savara is a biopharmaceutical company focused on treating rare lung diseases. Their lead candidate is designed for the treatment of autoimmune pulmonary alveolar proteinosis. This overall profitability curve is irrelevant to them. Their success depends solely on the results of clinical trials and regulatory approval of their drug.
Employees in the company, segment and market as a whole
Number of employees in the company Savara Inc.
Savara is a biopharmaceutical company specializing in rare lung diseases. Its small but growing team is focused on late-stage clinical trials. The growth on this chart is a clear signal that the company is approaching the potential launch of its lead product.
Share of the company's employees Savara Inc. within the market segment - Pharma immune
Savara is a pharmaceutical company specializing in developing drugs for rare lung diseases. This chart reflects the company's workforce strength in its highly specialized niche. The metric's dynamics are directly related to the intensity of clinical trials and the size of the scientific team working to create life-saving treatments for patients.
Number of employees in the market segment - Pharma immune
Savara Inc. is an orphan pharmaceutical company specializing in developing treatments for rare respiratory diseases. This chart shows employment trends in the highly specialized field of pulmonology. The growth in the number of clinical research and regulatory affairs specialists here is directly related to the progress of the company's key drug and its progress toward approval.
Number of employees in the market as a whole
Savara is a pharmaceutical company specializing in developing drugs to treat rare lung diseases. Its main product is an inhaled therapy for patients with pulmonary alveolar proteinosis. This chart illustrates how focusing on orphan diseases allows biotech companies like Savara to occupy important niches and create scientific jobs.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Savara Inc. (SVRA)
Savara Inc. is a biotech company specializing in rare lung diseases. This chart is a classic example of intellectual capital valuation. The company's value is based on market expectations for its lead drug candidate. The chart shows the high future value the market attributes to this development, per scientist.
%20of%20the%20company%20Savara%20Inc.%20(SVRA)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Savara-Inc.-SVRA&v=1772612592381 "Chart of market capitalization per employee (in thousands of dollars) of the company Savara Inc. (SVRA)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma immune
Savara is a biopharmaceutical company developing drugs for rare lung diseases. Its value is based on the potential of its lead drug candidate. This chart demonstrates the market's high valuation of its research assets and prospects based on its small team of scientists, which is typical for companies targeting orphan diseases.
%20by%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-immune&v=1772612592440 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma immune")
Market capitalization per employee (in thousands of dollars) for the overall market
Savara is a biopharmaceutical company specializing in developing treatments for rare respiratory diseases. The chart reflects the valuation of a company whose future depends on the success of a single key product. The high cost per employee indicates that the market is pricing in future revenue from sales of this important drug.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772612592456 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Savara Inc. (SVRA)
Savara is a late-stage biotech company developing inhaled drugs for rare lung diseases. This is R&D. This chart shows the company's capital burn rate: the amount of capital spent on each scientist and physician during expensive clinical trials.
%20Chart%20Savara%20Inc.%20(SVRA)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Savara-Inc.-SVRA&v=1772612592707 "Company Profit Per Employee (in thousands of dollars) Chart Savara Inc. (SVRA)")
Profit per employee (in thousands of dollars) in the market segment - Pharma immune
Savara (SVRA) is a late-stage biopharmaceutical company developing an inhaled drug (Molgradex) for the treatment of a rare lung disease. This loss per employee reflects the high cost of conducting the final, phase III clinical trials.
%20in%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-immune&v=1772612592741 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma immune")
Profit per employee (in thousands of dollars) for the market as a whole
Savara Inc. (SVRA) is a clinical-stage biotech company specializing in the treatment of rare lung diseases. It is an R&D company and is not profitable. This chart shows the company's capital burn rate: the operating loss per research team leading the development of a new drug through clinical trials.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772612592765 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Savara Inc. (SVRA)
Savara is a biopharmaceutical company developing treatments for rare lung diseases. This chart reflects the progress of its research and development commercialization. Revenue may be minimal at this stage, but as the drugs progress toward approval, this metric will reflect their commercial potential.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Savara-Inc.-SVRA&v=1772612592804 "Sales chart per company employee Savara Inc. (SVRA)")
Sales per employee in the market segment - Pharma immune
Savara (SVRA) is a biotech company specializing in developing inhaled therapies for rare lung diseases. This chart shows how productive their research team is, measuring revenue (from partnerships or early sales) per researcher compared to competitors.
Sales per employee for the market as a whole
Savara (SVRA) is a late-stage biopharmaceutical company specializing in the treatment of rare lung diseases. The company is preparing to commercialize its lead candidate. This chart illustrates its pre-launch readiness: a large team of specialists is dedicated to R&D and launch preparation, which is an investment in future revenue.
Short shares by company, segment and market as a whole
Shares shorted by company Savara Inc. (SVRA)
Savara Inc. is a biotech company developing inhaled therapies for rare lung diseases. Its success depends on a single key drug. The bearish sentiment shown in this chart reflects the high risk: investors are betting that its drug will fail to pass the final stage of clinical trials.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Savara-Inc.-SVRA&v=1772612592884 "Short Shares Chart for the Company Savara Inc. (SVRA)")
Shares shorted by market segment - Pharma immune
Savara is a biotech company developing a drug (Molgradex) to treat a rare lung disease (autoimmune pulmonary alveolar proteinosis). This metric measures pessimism. "Shorts" here are bets that their key drug will not receive FDA approval.
Shares shorted by the overall market
Savara (SVRA) is a biotech company specializing in treating rare lung diseases. It's a niche sector dependent on the success of clinical trials. This chart measures overall market pessimism. When investors are fearful (the indicator rises), they avoid "risky" biotechs that are burning cash, fearing they'll have a hard time raising new capital.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Savara Inc. (SVRA)
Savara is a biotech focused on rare lung diseases. Their fate hinges on one key drug (molgramostim). This chart measures the extremes of speculative expectations. It shows when the stock is "overbought" on the euphoria of trial data or "oversold" to the bottom on news of FDA delays.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Savara-Inc.-SVRA&v=1772612593020 "RSI 14 indicator chart for the company's stock Savara Inc. (SVRA)")
RSI 14 Market Segment - Pharma immune
Savara Inc. is a pharmaceutical company specializing in developing inhaled therapies for the treatment of rare lung diseases such as pulmonary alveolar proteinosis (PAP). This chart measures the overall momentum in the rare disease biotech sector. It helps assess whether the entire segment is overheated by expectations.
RSI 14 for the overall market
Savara (SVRA) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria is an opportunity to easily raise hundreds of millions of dollars for research. Market panic is the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast SVRA (Savara Inc.)
Savara is a biotech company developing inhaled therapies for rare lung diseases such as pulmonary alveolar proteinosis (aPAP). This chart shows the analysts' average 12-month forecast, representing their collective bet that clinical trials of their key drug, Molgradex, will be successful.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-SVRA-Savara-Inc.&v=1772612593168 "A chart showing analyst consensus forecasts for the expected stock price. SVRA (Savara Inc.)")
The difference between the consensus estimate and the actual stock price SVRA (Savara Inc.)
Savara (SVRA) is a biotech company focused on rare lung diseases. Its key asset is Molgradex, an inhaled drug for the treatment of autoimmune alveolar proteinosis. This chart shows the difference between the consensus estimate and the price, reflecting analysts' confidence in the success of this R&D pipeline.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-SVRA-Savara-Inc.&v=1772612593254 "A chart showing the difference between the consensus forecast and the actual stock price. SVRA (Savara Inc.)")
Analyst consensus forecast for stock prices by market segment - Pharma immune
Savara (SVRA) is a biopharmaceutical company focused on developing inhaled therapies for rare lung diseases such as pulmonary alveolar proteinosis. This chart shows general expectations for the immunotherapy sector. It reflects experts' confidence in the success of R&D in orphan lung diseases.
Analysts' consensus forecast for the overall market share price
Savara (SVRA) is an R&D biotech focused on rare lung diseases. They're burning cash waiting for approval. This chart, which measures overall market sentiment, is their risk appetite. During a downturn (pessimism), investors are unwilling to fund risky R&D projects.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Savara Inc.
Savara is a biotech company focused on orphan (rare) lung diseases. Their main asset (molgramostim) is an inhaled drug for the rare disease aPAP. This chart is a pure indicator of their main asset. It likely aggregates data from their final (Phase 3) clinical trials and market confidence in their chances of FDA approval.
AKIMA Market Segment Index - Pharma immune
Savara (SVRA) is a clinical-stage biotech focused on rare lung diseases; the company is developing an inhaled drug (Molgradex) for the treatment of autoimmune alveolar proteinosis. This summary metric evaluates R&D. The graph shows the segment average. This is a benchmark: how does this ultra-niche (R&D) rate (SVRA) differentiate it from the average pharma company?
The AKIM Index for the overall market
Savara is a biopharmaceutical company focused on rare respiratory diseases. Its key asset is an inhaled antibiotic for the treatment of aPAP. This chart, reflecting the market average, provides a macro backdrop. It helps assess how this company, which is approaching potential commercialization, fits within the context of overall economic trends.
